Boxes of the drug mifepristone sit on a shelf at the West Alabama Women's Center in Tuscaloosa, Ala., on March 16, 2022. On Tuesday, March 26, 2024, the U.S. Supreme Court will take up a case that could impact how women get access to mifepristone, one of the two pills used in the most common type of abortion in the nation.
"There is an ongoing set of data that is coming into the FDA on mifepristone," he said. "So if the data suggests something or tells us that there’s a real signal, we can’t promise we’re not going to act on that data."
Sen. Josh Hawley, R-Mo., wrote an April 28 letter to Makary regarding safety concerns about mifepristone.
SENATOR INTRODUCES LEGISLATION TO REIN IN WIDELY USED, CONTROVERSIAL ABORTION PILL
Mifepristone (Mifeprex) and Misoprostol, the two drugs used in a medication abortion, are seen at the Women's Reproductive Clinic, which provides legal medication abortion services, in Santa Teresa, New Mexico, on June 17, 2022. (ROBYN BECK/AFP via Getty Images)
Makary said during the interview with POLITICO that he has no plans to make "any changes" with policy regarding mifepristone, adding he would "continue to listen to folks that say they have concerns."
Fox News Digital reached out to the FDA and Sen. Hawley for comment.
Adam Sabes is a writer for Fox News Digital. Story tips can be sent to Adam.Sabes@fox.com and on Twitter @asabes10.
https://www.foxnews.com/politics/fda-chief-has-no-plans-abortion-pill-policy-changes-continues-safety-review